Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/resource/nanopub/NP911083.RASLkXpW3GjLGnvdsGUQv1Z4FSIbY5XXN7_2uP2ykr5yc130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP911083.RASLkXpW3GjLGnvdsGUQv1Z4FSIbY5XXN7_2uP2ykr5yc130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP911083.RASLkXpW3GjLGnvdsGUQv1Z4FSIbY5XXN7_2uP2ykr5yc130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP911083.RASLkXpW3GjLGnvdsGUQv1Z4FSIbY5XXN7_2uP2ykr5yc130_provenance.
- NP911083.RASLkXpW3GjLGnvdsGUQv1Z4FSIbY5XXN7_2uP2ykr5yc130_assertion description "[We retrospectively studied four cases of t-MDS/AML among 210 (1.9%) consecutive patients with CLL treated at a single center with fludarabine and cyclophosphamide (FC) either as the first- or second-line therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP911083.RASLkXpW3GjLGnvdsGUQv1Z4FSIbY5XXN7_2uP2ykr5yc130_provenance.
- NP911083.RASLkXpW3GjLGnvdsGUQv1Z4FSIbY5XXN7_2uP2ykr5yc130_assertion evidence source_evidence_literature NP911083.RASLkXpW3GjLGnvdsGUQv1Z4FSIbY5XXN7_2uP2ykr5yc130_provenance.
- NP911083.RASLkXpW3GjLGnvdsGUQv1Z4FSIbY5XXN7_2uP2ykr5yc130_assertion SIO_000772 21775097 NP911083.RASLkXpW3GjLGnvdsGUQv1Z4FSIbY5XXN7_2uP2ykr5yc130_provenance.
- NP911083.RASLkXpW3GjLGnvdsGUQv1Z4FSIbY5XXN7_2uP2ykr5yc130_assertion wasDerivedFrom befree-2016 NP911083.RASLkXpW3GjLGnvdsGUQv1Z4FSIbY5XXN7_2uP2ykr5yc130_provenance.
- NP911083.RASLkXpW3GjLGnvdsGUQv1Z4FSIbY5XXN7_2uP2ykr5yc130_assertion wasGeneratedBy ECO_0000203 NP911083.RASLkXpW3GjLGnvdsGUQv1Z4FSIbY5XXN7_2uP2ykr5yc130_provenance.
- befree-2016 importedOn "2016-02-19" NP911083.RASLkXpW3GjLGnvdsGUQv1Z4FSIbY5XXN7_2uP2ykr5yc130_provenance.